IRTC - iRhythm Remains Insulated From Peers Double-Digit Growth By 2021 Is Likely

• iRhythm has key differentiators that insulate the company from peers and provide additional value to the clinical setting, backed by AI software and over 30 clinical studies.
• Shareholders have enjoyed over 250% in returns over the single-year period, with most upside seen on the back of new CPT-1 codes and physician fee scheduling.
• Shares have formed an ascending channel since August, with a new level of support formed at today's trading, following a retracement in October.
• Covid-19 has highlighted the company's exposure to telehealth and their service model aligns with the current patient / specialist narrative of service delivery.
• We hold a bullish long-term outlook for the company, and set a price target of $270 over the coming 2-year period in line with our thesis.

For further details see: